Journals / Türk Oftalmoloji Dergisi / 2009 / Cilt: 39 - Sayı: 3

The visual acuity results and complications after intravitreal triamcinolone acetonide ınjection for clinically significant diabetic macular edema

Klinik olarak anlamlı diyabetik makula ödeminde intravitreal triamsinolone asetonid enjeksiyonu sonrası görsel sonuçlar ve komplikasyonlar

Pages
205–210
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: 0.1 ml/4mg injection of IVTA appears to be a cost effective treatment choice which improves BCVA and CMT values in clinically significant DME in eligible patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To investigate the anatomic and the best corrected visual acuity (BCVA) response after intravitreal triamcinolone acetonide injection (IVTA 0.1ml/4mg) for treating clinically significant diabetic macular edema (DME).
📊
Key Findings & Data:METHODS: Sixty five eyes of 45 patients with clinically significant DME followed up in Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology were included in the study.
💡
Conclusion & Impact:CONCLUSION: 0.1 ml/4mg injection of IVTA appears to be a cost effective treatment choice which improves BCVA and CMT values in clinically significant DME in eligible patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PURPOSE: To investigate the anatomic and the best corrected visual acuity (BCVA) response after intravitreal triamcinolone acetonide injection (IVTA 0.1ml/4mg) for treating clinically significant diabetic macular edema (DME). METHODS: Sixty five eyes of 45 patients with clinically significant DME followed up in Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology were included in the study. The mean follow-up was 7,6±3,6 (3-14 months) months. The BCVA, central macular thickness (CMT) with optic cohorence tomography (OCT) and intraocular pressure values before and 1 week, 1 month, 3 months, 6 months and 12 months after IVTA injection were noted. RESULTS: BCVA improved in 41 (63%) eyes at 1 month, 28 (43%) eyes at 3 months and 2 eyes at 6 month after injection. The mean CMT at baseline,1.month, 3.months, 6.months and 12.months were recpectively 400,58 ± 136 µm, 293,36 ± 115 µm, 258,97 ± 110 µm, 308,59 ± 158 µm. The mean IOP before injection, at 1.week, 1.month, 3.months, 6 months and 12.months after the injection were respectively 17,9 ± 2,2 mmHg, 18,7 ± 3,8 mmHg, 17,4 ± 4,1 mmHg, 16,2 ± 1,9 mmHg, 16,7 ± 1,5 mmHg. CONCLUSION: 0.1 ml/4mg injection of IVTA appears to be a cost effective treatment choice which improves BCVA and CMT values in clinically significant DME in eligible patients.

Özet

AMAÇ: Diyabete bağlı klinik olarak anlamlı makula ödemi olan gözlerde intravitreal 0,1ml /4mg triamsinolon asetonid enjeksiyonu (İVTA) sonrasında düzeltilmiş en iyi görme keskinliği (DEİGK) ve santral makula kalınlığı (SMK) değişimlerini incelemek.MATERYAL/METOD: İ.Ü İstanbul Tıp Fakültesi Göz Hastalıkları Anabilim Dalı Retina Departmanı’nda takip edilen ve ETDRS kriterlerine göre klinik olarak anlamlı diyabetik makula ödemi saptanan 45 hastanın 65 gözü çalışmaya alındı. Ortalama takip sűresi 7,6±3,6 (3-14 ay) ay idi. Hastalarda DEİGK, göz içi basınçları (GİB) ve optik koherens tomografi (OKT) ile SMK değerleri belirlendi. Hastaların enjeksiyon sonrası 1.gün, 1.hafta, 1.ay, 3.ay, 6.ay, ve 12. ayda kontrolleri yapıldı.BULGULAR: Birinci ayda 41 (% 63) gözde DEİGK’de artış olurken 3.ay kontrollerde 28 (% 43) gözde, 6.ayda ise 2 gözde DEİGK’de artış görüldü. Ortalama SMK değerleri enjeksiyon öncesi 400,58 ± 136 µm, 1. ayda 293,36 ± 115 µm, 3. ayda 258,97 ± 110 µm, 6.ayda 308,59 ± 158 µm olarak bulundu. Hastaların ortalama GİB değerleri enjeksiyon öncesi 16,7 ± 1,8 mmHg iken enjeksiyon sonrası 1.haftada 17,9 ± 2,2 mmHg, 1.ayda 18,7 ± 3,8 mmHg, 3.ayda 17,4 ± 4,1 mmHg, 6.ayda 16,2 ± 1,9 mmHg, 12.ayda ise 16,7 ± 1,5 mmHg olarak ölçüldü. SONUÇ: İVTA enjeksiyonu, klinik olarak anlamlı makula ödemi olan hastalarda SMK’daki azalma ve buna eşlik eden görme keskinliğindeki artış ile etkisini gösteren uygun hastalarda maliyeti düşük halen geçerli bir tedavi seçeneğidir.

🔖

Cite This Article

KIR, N., YENİAD, B., AKARÇAY, K., TUNCER, S., OVALI, T., YÜKSEL, S. B. (2022). The visual acuity results and complications after intravitreal triamcinolone acetonide ınjection for clinically significant diabetic macular edema. Türk Oftalmoloji Dergisi, Cilt: 39 - Sayı: 3, 205–210. https://ajindex.com/articles/638520

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Bresnick GH. Diabetic macular edema: a review. Ophthalmology 1986
  2. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmology 1985
  3. Jonas JB, Akkoyun Kreissig I, Degenring RF. Diffuse diabetic macular edema treated by intravitreal triamcinolo- ne acetonide: a comparative, non-randomised study. Br J Ophthalmol. 2005
  4. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroids. Am J Ophthalmol 1980
  5. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986
  6. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema.Oph-thalmology 2002
  7. Jonas JB, Kreissig I, Hugger P, et al. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003
  8. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992
  9. Özdek S, Bahçeci UA, Gürelik G, Hasanreisoğlu B. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. Journal of Diabetes and its Complications 2006
  10. Schindler RH, Chandler DB, Thresher R, et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982
  11. Kivilcim M, Peyman GA, EI-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicon-filled eyes. Ophthalmic Surg Laser 2000
  12. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophtalmology 2003
  13. McLean EB. Inadvertent injection of corticosteroids into the choroidal vasculature. Am J Ophthalmol 1975
  14. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophtalmology 2004
  15. Jonas JB, Kreissig I, Soefker A, et al. Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2003
  16. Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macu